+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase Not Applicable
Age: 18Years +
All Genders
ID06629207

Using Artificial Intelligence and Molecular Imaging to Predict Parkinsons Disease Risk in Adults with REM Sleep Behavior Disorder

Led by Insel Gruppe AG, University Hospital Bern · Updated on 2024-11-08

20

Participants Needed

1

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are studying individuals with isolated Rapid Eye Movement REM Sleep Behavior Disorder iRBD to better understand how this condition progresses and to identify markers that might predict the development of Parkinsons disease, dementia with Lewy bodies, or multiple system atrophy. The study uses artificial intelligence to analyze brain imaging data and aims to develop reliable methods to forecast and categorize patients at risk of converting to these neurodegenerative diseases. Participants will undergo advanced imaging procedures, including PETCT scans with 18-FDG, SPECT scans using 123 I-FP-CIT DATSCAN, and MRI scans to rule out structural brain issues. These scans are performed using specialized equipment and specific timing protocols, such as imaging 30 minutes after injection for PETCT and within 4 hours after injection for SPECT. The study is designed as an interventional trial focusing on imaging devices. Throughout the study, participants will be clinically assessed, and imaging results will be collected and analyzed to evaluate the accuracy of deep learning models in predicting disease progression over a follow-up period expected to last 48 months. The main outcome is to measure how well the AI model predicts neurodegenerative conversion in iRBD patients. Secondary outcomes include comparing predicted and actual conversion risks and evaluating the models accuracy specifically for Parkinsons disease conversion. Participants will be monitored regularly to ensure safety and data quality during the study period.

CONDITIONS

Brief Title

Artificial Intelligence in Molecular Imaging: Predicting Parkinson's Risk in REM Sleep Behavior Disorder

Research Team

A

Axel Rominger, Prof. Dr. med.

F

Franziska Strunz, PhD

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here